Is GW7 86034 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use GW7 86034? Is GW7 86034 safe for nursing mother and child? Does GW7 86034 extracts into breast milk? Does GW7 86034 has any long term or short term side effects on infants? Can GW7 86034 influence milk supply or can GW7 86034 decrease milk supply in lactating mothers?

• DrLact safety Score for GW7 86034 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of GW7 86034 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that GW7 86034 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using GW7 86034 .
• It is recommended to evaluate the advantage of not breastfeeding while using GW7 86034 Vs not using GW7 86034 And continue breastfeeding.
• While using GW7 86034 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of several neoplastic diseases. At latest update, relevant published data on excretion into breast milk were not found. Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, it should be wait for 10 half-lives (T ½). It means that 13 days should be waited before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

No information is available on the clinical use of GW7 86034 during breastfeeding. Because GW7 86034 is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 31 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during GW7 86034 therapy and for 2 weeks after the final dose.